S&P 500   4,008.01 (-0.39%)
DOW   32,223.42 (+0.08%)
QQQ   298.23 (-1.23%)
AAPL   145.30 (-1.23%)
MSFT   261.51 (+0.15%)
FB   200.07 (+0.73%)
GOOGL   2,287.00 (-1.47%)
AMZN   2,216.21 (-1.99%)
TSLA   723.37 (-6.01%)
NVDA   172.38 (-2.64%)
BABA   86.57 (-1.61%)
NIO   14.55 (+1.68%)
AMD   94.13 (-1.04%)
CGC   5.73 (-3.21%)
MU   70.53 (-1.93%)
T   20.30 (+2.32%)
GE   74.67 (-0.51%)
F   13.01 (-3.63%)
DIS   105.04 (-2.13%)
AMC   11.74 (-0.59%)
PFE   50.68 (+1.52%)
PYPL   77.53 (-1.65%)
NFLX   186.51 (-0.60%)
S&P 500   4,008.01 (-0.39%)
DOW   32,223.42 (+0.08%)
QQQ   298.23 (-1.23%)
AAPL   145.30 (-1.23%)
MSFT   261.51 (+0.15%)
FB   200.07 (+0.73%)
GOOGL   2,287.00 (-1.47%)
AMZN   2,216.21 (-1.99%)
TSLA   723.37 (-6.01%)
NVDA   172.38 (-2.64%)
BABA   86.57 (-1.61%)
NIO   14.55 (+1.68%)
AMD   94.13 (-1.04%)
CGC   5.73 (-3.21%)
MU   70.53 (-1.93%)
T   20.30 (+2.32%)
GE   74.67 (-0.51%)
F   13.01 (-3.63%)
DIS   105.04 (-2.13%)
AMC   11.74 (-0.59%)
PFE   50.68 (+1.52%)
PYPL   77.53 (-1.65%)
NFLX   186.51 (-0.60%)
S&P 500   4,008.01 (-0.39%)
DOW   32,223.42 (+0.08%)
QQQ   298.23 (-1.23%)
AAPL   145.30 (-1.23%)
MSFT   261.51 (+0.15%)
FB   200.07 (+0.73%)
GOOGL   2,287.00 (-1.47%)
AMZN   2,216.21 (-1.99%)
TSLA   723.37 (-6.01%)
NVDA   172.38 (-2.64%)
BABA   86.57 (-1.61%)
NIO   14.55 (+1.68%)
AMD   94.13 (-1.04%)
CGC   5.73 (-3.21%)
MU   70.53 (-1.93%)
T   20.30 (+2.32%)
GE   74.67 (-0.51%)
F   13.01 (-3.63%)
DIS   105.04 (-2.13%)
AMC   11.74 (-0.59%)
PFE   50.68 (+1.52%)
PYPL   77.53 (-1.65%)
NFLX   186.51 (-0.60%)
S&P 500   4,008.01 (-0.39%)
DOW   32,223.42 (+0.08%)
QQQ   298.23 (-1.23%)
AAPL   145.30 (-1.23%)
MSFT   261.51 (+0.15%)
FB   200.07 (+0.73%)
GOOGL   2,287.00 (-1.47%)
AMZN   2,216.21 (-1.99%)
TSLA   723.37 (-6.01%)
NVDA   172.38 (-2.64%)
BABA   86.57 (-1.61%)
NIO   14.55 (+1.68%)
AMD   94.13 (-1.04%)
CGC   5.73 (-3.21%)
MU   70.53 (-1.93%)
T   20.30 (+2.32%)
GE   74.67 (-0.51%)
F   13.01 (-3.63%)
DIS   105.04 (-2.13%)
AMC   11.74 (-0.59%)
PFE   50.68 (+1.52%)
PYPL   77.53 (-1.65%)
NFLX   186.51 (-0.60%)
NASDAQ:ADMS

Adamas Pharmaceuticals (ADMS) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$8.22
$8.22
50-Day Range
$7.97
$8.23
52-Week Range
$4.02
$9.15
Volume
N/A
Average Volume
692,487 shs
Market Capitalization
$376.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.82

Receive ADMS News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Adamas Pharmaceuticals logo

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Headlines

Why Supernus' Acquisition of Adamas Is a Smart Move
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADMS
Employees
138
Year Founded
N/A

Sales & Book Value

Annual Sales
$74.46 million
Book Value
($0.47) per share

Profitability

Net Income
$-57.40 million
Pretax Margin
-71.11%

Debt

Price-To-Earnings

Miscellaneous

Free Float
37,133,000
Market Cap
$376.37 million
Optionable
Optionable

Company Calendar

Last Earnings
11/11/2021
Today
5/16/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.73 out of 5 stars

Medical Sector

876th out of 1,423 stocks

Pharmaceutical Preparations Industry

427th out of 678 stocks

Analyst Opinion: 1.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions

Is Adamas Pharmaceuticals a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last twelve months. There are currently 6 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Adamas Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADMS, but not buy additional shares or sell existing shares.
View analyst ratings for Adamas Pharmaceuticals
or view top-rated stocks.

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) announced its earnings results on Thursday, November, 11th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.21. The specialty pharmaceutical company earned $25.90 million during the quarter, compared to analysts' expectations of $25.07 million.
View Adamas Pharmaceuticals' earnings history
.

What price target have analysts set for ADMS?

6 brokers have issued 12 month price targets for Adamas Pharmaceuticals' shares. Their forecasts range from $8.00 to $9.10. On average, they anticipate Adamas Pharmaceuticals' stock price to reach $8.53 in the next year. This suggests a possible upside of 3.8% from the stock's current price.
View analysts' price targets for Adamas Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Adamas Pharmaceuticals' key executives?
Adamas Pharmaceuticals' management team includes the following people:
What is Neil McFarlane's approval rating as Adamas Pharmaceuticals' CEO?

2 employees have rated Adamas Pharmaceuticals CEO Neil McFarlane on Glassdoor.com. Neil McFarlane has an approval rating of 100% among Adamas Pharmaceuticals' employees. This puts Neil McFarlane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adamas Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sorrento Therapeutics (SRNE), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Sangamo Therapeutics (SGMO), Dynavax Technologies (DVAX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL) and Nabriva Therapeutics (NBRV).

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

What is Adamas Pharmaceuticals' stock price today?

One share of ADMS stock can currently be purchased for approximately $8.22.

How much money does Adamas Pharmaceuticals make?

Adamas Pharmaceuticals has a market capitalization of $376.37 million and generates $74.46 million in revenue each year. The specialty pharmaceutical company earns $-57.40 million in net income (profit) each year or ($1.700010) on an earnings per share basis.

How many employees does Adamas Pharmaceuticals have?

Adamas Pharmaceuticals employs 138 workers across the globe.

What is Adamas Pharmaceuticals' official website?

The official website for Adamas Pharmaceuticals is www.adamaspharma.com.

How can I contact Adamas Pharmaceuticals?

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at (510) 450-3500, via email at [email protected], or via fax at 510-428-0519.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.